Last update: Aug. 6, 2017

Glibenclamide

Very Low Risk for breastfeeding


Safe. Compatible.
Not risky for breastfeeding or infant.

Sulfonylureas stimulate endogenous insulin secretion. They can cause hypoglycemia.

Its pharmacokinetic data (moderately high molecular weight and very high percentage of plasma protein binding) explain the zero or negligible passage into breast milk observed (Serrano 2014, Glatstein 2009, Feig 2007and 2005).

Although blood sugar levels were normal in an infant whose mother was taking glibencamide (Feig 2005), one author suggests monitoring for symptoms of hypoglycemia in the infant (Glatstein 2009).

List of WHO essential medicines: compatible with breastfeeding (WHO / UNICEF 2002).

Diet, exercise, and breastfeeding improve blood sugar levels.


See below the information of this related product:

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Glibenclamide is also known as


Glibenclamide in other languages or writings:

Tradenames

Main tradenames from several countries containing Glibenclamide in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 70 - 84 %
Molecular weight 494 daltons
Protein Binding 99 %
VD 0,7 l/Kg
Tmax 2 - 6 hours
T1/2 2 - 10 hours
M/P ratio 0 -
Theoretical Dose < 0,0007 mg/Kg/d
Relative Dose < 1 %

References

  1. AEMPS. Glibenclamida. Ficha técnica. 2016 Full text (in our servers)
  2. Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015 Abstract
  3. Rowe H, Baker T, Hale TW. Maternal medication, drug use, and breastfeeding. Pediatr Clin North Am. 2013 Feb;60(1):275-94. Abstract
  4. Sanofi. Glibenclamide. Drug Summary. 2012 Full text (in our servers)
  5. Refuerzo JS. Oral hypoglycemic agents in pregnancy. Obstet Gynecol Clin North Am. 2011 Abstract
  6. Glatstein MM, Djokanovic N, Garcia-Bournissen F, Finkelstein Y, Koren G. Use of hypoglycemic drugs during lactation. Can Fam Physician. 2009 Abstract Full text (link to original source) Full text (in our servers)
  7. Feig DS, Briggs GG, Koren G. Oral antidiabetic agents in pregnancy and lactation: a paradigm shift? Ann Pharmacother. 2007 Abstract
  8. Feig DS, Briggs GG, Kraemer JM, Ambrose PJ, Moskovitz DN, Nageotte M, Donat DJ, Padilla G, Wan S, Klein J, Koren G. Transfer of glyburide and glipizide into breast milk. Diabetes Care. 2005 Abstract Full text (link to original source) Full text (in our servers)
  9. WHO / UNICEF. BREASTFEEDING AND MATERNAL MEDICATION Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs. Department of Child and Adolescent Health and Development (WHO/UNICEF) 2002 Full text (link to original source) Full text (in our servers)

Total visits

8,219

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM